11.6. Retinal Disorders

Ranibizumab Biosimilar (Ongavia)	This High-Cost Drug has been approved for the following indications:- Neovascular (wet) age-related macular degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), and Choroidal neovascularisation.
	Ranibizumab and pegaptanib for the treatment of age-related macular degeneration NICE Guidance TA155
For more information and NICE Guidance Click Here	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion NICE Guidance TA283
	Ranibizumab for treating diabetic macular oedema NICE Guidance TA274
	Ranibizumab for treating choroidal neovascularisation associated with pathological myopia NICE Guidance TA298

Faricimab	This High-Cost Drug has been approved for the following indications:- Diabetic Macular Oedema (DMO), and Neovascular (wet) age-related macular degeneration (wetAMD)
	Faricimab for treating diabetic macular oedema NICE Guidance TA799
For more information and NICE Guidance Click Here	Faricimab for treating wet age-related macular degeneration NICE Guidance TA800

Brolucizumab	This High-Cost Drug has been approved for the following indications:- Visual impairment due to diabetic macular oedema in adults. Brolucizumab will be reserved as a last line treatment option following failure to either aflibercept, faricimab and ranibizumab.
For more information and NICE Guidance Click Here	Brolucizumab for treating diabetic macular oedema NICE Guidance TA820

Dexamethasone intravitreal implant (Ozurdex)	This High-Cost Drug has been approved for the following indications:- Treatment of diabetic macular oedema (DMO)
For more information and NICE Guidance Click Here	Dexamethasone intravitreal implant for treating diabetic macular oedema NICE Guidance TA824